These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 2643296)

  • 1. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
    Hortobagyi GN; Frye D; Buzdar AU; Ewer MS; Fraschini G; Hug V; Ames F; Montague E; Carrasco CH; Mackay B
    Cancer; 1989 Jan; 63(1):37-45. PubMed ID: 2910423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
    Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
    Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Høst H
    Eur J Cancer; 1990 Jan; 26(1):45-8. PubMed ID: 2138477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
    Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
    Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
    Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
    Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
    Perez DJ; Harvey VJ; Robinson BA; Atkinson CH; Dady PJ; Kirk AR; Evans BD; Chapman PJ
    J Clin Oncol; 1991 Dec; 9(12):2148-52. PubMed ID: 1960557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
    Wishart GC; Bissett D; Paul J; Jodrell D; Harnett A; Habeshaw T; Kerr DJ; Macham MA; Soukop M; Leonard RC
    J Clin Oncol; 1994 Sep; 12(9):1771-7. PubMed ID: 8083699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
    Michelotti A; Venturini M; Tibaldi C; Bengala C; Gallo L; Carnino F; Del Mastro L; Lionetto R; Montanaro E; Rosso R; Conte P
    Breast Cancer Res Treat; 2000 Jan; 59(2):133-9. PubMed ID: 10817348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
    ; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
    J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
    Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
    J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.